Nationwide Trends in Incidence, Healthcare Utilization, and Mortality in Hospitalized Acute Myocardial Infarction Patients in Taiwan
Completed
- Conditions
- Acute Myocardial Infarction
- First Posted Date
- 2023-08-03
- Last Posted Date
- 2023-08-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 124018
- Registration Number
- NCT05974397
- Locations
- 🇨🇳
Novartis, Taipei, Taiwan
Real-life Study of the Characteristics of Patients Treated With Ilaris® (Canakinumab) for Gouty Arthritis in France
Completed
- Conditions
- Gouty Arthritis
- First Posted Date
- 2023-07-28
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 15
- Registration Number
- NCT05964946
- Locations
- 🇫🇷
Novartis, Paris, France
Comparative Effectiveness of Entresto (Sacubitril/Valsartan) Versus ACEi/ARB in de Novo Heart Failure Patients
Completed
- Conditions
- de Novo Heart Failure
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 9870
- Registration Number
- NCT05963282
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Post Marketing Study to Evaluate the Safety and Effectiveness of Brolucizumab in Patients With Diabetic Macular Edema.
Not yet recruiting
- Conditions
- Diabetic Macular Edema
- Interventions
- Other: brolucizumab
- First Posted Date
- 2023-07-25
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 66
- Registration Number
- NCT05959304
Assessment of Immune Response in Multiple Sclerosis Patients With COVID-19/Vaccination Treated With Ofatumumab and Other Disease Modifying Therapies
Completed
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 61
- Registration Number
- NCT05950308
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
- First Posted Date
- 2023-07-17
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 232
- Registration Number
- NCT05948943
- Locations
- 🇪🇸
Novartis Investigative Site, Madrid, Spain
🇺🇸Cinn Children Hosp Medical Center, Cincinnati, Ohio, United States
🇺🇸Baylor College Of Medicine, Houston, Texas, United States
Asciminib RMP Study
Recruiting
- Conditions
- Chronic Myeloid Leukemia
- Interventions
- Other: Asciminib
- First Posted Date
- 2023-07-13
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 100
- Registration Number
- NCT05943522
- Locations
- 🇰🇷
Novartis Investigative Site, Taegu, Korea, Republic of
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
- First Posted Date
- 2023-07-11
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 450
- Registration Number
- NCT05939414
- Locations
- 🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸Stanford University, Palo Alto, California, United States
🇺🇸UCSF, San Francisco, California, United States
Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 50
- Registration Number
- NCT05935215
- Locations
- 🇬🇧
Novartis Investigative Site, Newcastle upon Tyne, United Kingdom
Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of secukinumAb in Adult Patients With Moderate to Severe Hidradenitis Suppurativa.
Recruiting
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Other: secukinumab
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 600
- Registration Number
- NCT05921994
- Locations
- 🇩🇪
Novartis Investigative Site, Wuppertal, Germany
© Copyright 2025. All Rights Reserved by MedPath